MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area
- 1 August 1986
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 25 (8) , 939-941
- https://doi.org/10.1016/0028-3908(86)90025-0
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatmentNeuroscience Letters, 1985
- Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the MouseJournal of Neurochemistry, 1985
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984
- Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonismNature, 1984
- The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and ManCanadian Journal of Neurological Sciences, 1984
- Reduction in motor responding of the mouse by actions of dopamine agonists in the midbrainNeuropharmacology, 1983